Loss of exclusivity is the most financially impactful lifecycle transition in pharma. Biosimilar or generic entry can erode the majority of branded revenue within 18 months. Yet most organizations begin defense planning too late, with fragmented intelligence, and make timing decisions based on instinct rather than modeled scenarios.
Behavior Labs delivers lifecycle decision intelligence for biosimilar defense — connecting ANDA/BPCIA filing surveillance, interchangeability tracking, authorized generic scenario modeling, payer switching threshold analysis, and franchise transition strategy into a compounding intelligence platform that starts working years before your exclusivity date.
Biosimilar defense is a multi-year strategic program, not a single decision. The platform delivers compounding intelligence across filing surveillance, scenario modeling, payer analysis, and transition planning — starting years before the exclusivity date and continuing through franchise migration.
Monitor ANDA and BPCIA filings, track biosimilar interchangeability designations, and model competitive entry timelines with continuously updated intelligence. Know which biosimilar applicants are advancing, where they are in the review cycle, and when market entry is likely.
Model authorized generic launch timing, pricing, and market share scenarios against multiple biosimilar entry configurations. Determine the optimal AG launch window that maximizes franchise value across the transition period.
Use synthetic persona panels to predict HCP and payer switching thresholds at various discount levels. Model formulary committee decision dynamics to set contracting strategy based on modeled behavior rather than guesswork.
Connect LOE defense to next-generation asset positioning. Model patient transition pathways, design retention programs, and optimize the timing of lifecycle extension investments relative to competitive entry scenarios.
The patent cliff is approaching for some of pharma's largest franchises. The difference between proactive defense and reactive response is measured in billions.
See how lifecycle decision intelligence transforms biosimilar defense from reactive crisis management to proactive strategic planning.
